How have ONVO shares performed in 2023?

Organovo's stock was trading at $1.41 at the beginning of the year. Since then, ONVO stock has decreased by 16.3% and is now trading at $1.18. View the best growth stocks for 2023 here .

When is Organovo's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 8th 2024. View our ONVO earnings forecast .

How were Organovo's earnings last quarter?

Organovo Holdings, Inc. (NASDAQ:ONVO) announced its earnings results on Thursday, August, 8th. The medical research company reported ($1.00) EPS for the quarter, hitting the consensus estimate of ($1.00). The medical research company earned $0.67 million during the quarter, compared to the consensus estimate of $0.77 million. Organovo had a negative trailing twelve-month return on equity of 129.61% and a negative net margin of 4,061.12%.

When did Organovo's stock split?

Organovo shares reverse split on Wednesday, August 19th 2020. The 1-20 reverse split was announced on Monday, August 17th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 18th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Taylor Crouch's approval rating as Organovo's CEO?

3 employees have rated Organovo Chief Executive Officer Taylor Crouch on Glassdoor.com . Taylor Crouch has an approval rating of 38% among the company's employees. This puts Taylor Crouch in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Organovo own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Organovo investors own include Brainstorm Cell Therapeutics (BCLI) , NVIDIA (NVDA) , Aerojet Rocketdyne (AJRD) , Blackstone (BX) , LADENBURG THALM/SH SH (LTS) , Advanced Micro Devices (AMD) , Exelixis (EXEL) , Micron Technology (MU) , Novavax (NVAX) and OPKO Health (OPK) .

Who are Organovo's major shareholders?

Organovo's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David Gobel and Douglas Jay Cohen . View institutional ownership trends .

How do I buy shares of Organovo?

Shares of ONVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Organovo Stock Price, News & Analysis (NASDAQ:ONVO)

$1.18

0.00 (0.00%)

(As of 11/28/2023 ET)

Compare

Today's Range: $1.16
▼
$1.20
50-Day Range: $1.05
▼
$1.84
52-Week Range: $1.00
▼
$3.40

Volume: 28,024 shs
Average Volume: 76,325 shs
Market Capitalization: $10.29 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Organovo MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Bearish
5.09% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.94
Based on 2 Articles This Week
Insider Trading: Selling Shares
$31,763 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.75) to ($1.91) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.23 out of 5 stars

Medical Sector

921st out of 949 stocks

Biological Products, Except Diagnostic Industry

158th out of 160 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Organovo.

2.0

Short Interest

Percentage of Shares Shorted
5.09% of the outstanding shares of Organovo have been sold short.
Short Interest Ratio / Days to Cover
Organovo has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Organovo has recently increased by 2.40%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Organovo does not currently pay a dividend.
Dividend Growth
Organovo does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ONVO.

3.3

News and Social Media Coverage

News Sentiment
Organovo has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Organovo this week, compared to 0 articles on an average week.
Search Interest
15 people have searched for ONVO on MarketBeat in the last 30 days. This is an increase of 650% compared to the previous 30 days.
MarketBeat Follows
3 people have added Organovo to their MarketBeat watchlist in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Organovo insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $31,763.00 in company stock.
Percentage Held by Insiders
Only 4.00% of the stock of Organovo is held by insiders.
Percentage Held by Institutions
Only 9.14% of the stock of Organovo is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Organovo are expected to decrease in the coming year, from ($1.75) to ($1.91) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Organovo is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Organovo is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Organovo has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Organovo Stock (NASDAQ:ONVO)

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.

ONVO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ONVO Stock News Headlines

November 24, 2023 | americanbankingnews.com

StockNews.com Initiates Coverage on Organovo (NASDAQ:ONVO)

November 20, 2023 | americanbankingnews.com

Insider Selling: Organovo Holdings, Inc. (NASDAQ:ONVO) Director Sells $31,763.34 in Stock

November 28, 2023 | RYSE INC. (Ad)

Secure your stake in the Smart Home industry.

Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.

November 13, 2023 | msn.com

OVNO Continues Developing Breakthrough Treatments

November 13, 2023 | finance.yahoo.com

CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan

November 11, 2023 | finance.yahoo.com

Organovo Holdings Second Quarter 2024 Earnings: US$0.46 loss per share (vs US$0.38 loss in 2Q 2023)

November 8, 2023 | finance.yahoo.com

Organovo Highlights FXR314 Combination Therapy Potential and Plan

November 7, 2023 | msn.com

ONVO, FATH and BYU among mid-day movers

November 28, 2023 | RYSE INC. (Ad)

Secure your stake in the Smart Home industry.

Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.

October 10, 2023 | finance.yahoo.com

ONVO: A Company With Great Technology to Impact Health Care

September 8, 2023 | finance.yahoo.com

Organovo to Participate in the H.C. Wainwright Global Investment Conference

August 25, 2023 | finance.yahoo.com

Is Organovo Holdings (ONVO) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap

August 23, 2023 | finance.yahoo.com

Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data

August 16, 2023 | msn.com

Onvo receives $3 million grant from PennDOT to enhance electric vehicle charging infrastructure

July 29, 2023 | seekingalpha.com

ONVO Organovo Holdings, Inc.

July 20, 2023 | msn.com

Onvo introduces first public fast electric vehicle chargers on I-81 stretch

June 7, 2023 | fool.com

Organovo (NASDAQ: ONVO)

March 21, 2023 | finance.yahoo.com

Organovo Announces FXR Program

February 10, 2023 | finance.yahoo.com

Will Organovo Holdings (NASDAQ:ONVO) Spend Its Cash Wisely?

October 25, 2022 | finance.yahoo.com

Organovo Holdings, Inc. (ONVO)

October 17, 2022 | finance.yahoo.com

Trends in 3D-Printing Materials Technology and the Global Market for the Most Promising New 3D-Printing Materials Applications - Yahoo Finance

October 12, 2022 | benzinga.com

Human Liver Models Market Size Share Trends Growth Demand and Competitive Analysis Insights 2022-2029 | D - Benzinga

October 9, 2022 | globenewswire.com

3D Bioprinting Market Size to Touch Valuation of $1.5 Billion by 2028 | Inkjet Technology Generates More than 38% Revenue of Bioprinting Market - GlobeNewswire

October 3, 2022 | seekingalpha.com

ARKG: Too Hard To Pin Down, Too Volatile For Comfort (BATS:ARKG) - Seeking Alpha

September 30, 2022 | prnewswire.com

Global Laboratory Animal Models, 3D Cultures and Organoids Markets, 2019-2021 & 2022-2027 - Opportunities in Organoids in Drug Development, Personalized Medicine and Transplantational Medicine - PR Newswire

September 30, 2022 | businesswire.com

Global Human Liver Model Market Report 2022: Emerging 3D and 2D Trends in Modeling Human Liver Disease in Vitro Fuel Growth - ResearchAndMarkets.com - Business Wire

September 29, 2022 | businesswire.com

3D Bioprinting Global Market Report 2022: Long-term Forecasts to 2026 & 2031 Featuring Organovo Holdings, Allevi, Cellink, Aspect Biosystems, & 3D Systems - ResearchAndMarkets.com - Business Wire

See More Headlines

Receive ONVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Organovo and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/08/2019
Today: 11/28/2023
Next Earnings (Estimated): 2/08/2024
Fiscal Year End: 3/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ONVO
CUSIP: N/A
CIK: 1497253
Web: www.organovo.com
Phone: (858) 224-1000
Fax: N/A
Employees: 23
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($2.14)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-17,260,000.00
Net Margins: -4,061.12%
Pretax Margin: -5,093.21%
Return on Equity: -129.61%
Return on Assets: -105.15%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.18
Quick Ratio: 5.18

Sales & Book Value

Annual Sales: $368,000.00
Price / Sales: 27.96
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.76 per share
Price / Book: 0.67

Miscellaneous

Outstanding Shares: 8,720,000
Free Float: 8,284,000
Market Cap: $10.29 million
Optionable: Optionable
Beta: 0.84

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. Keith E. Murphy (Age 51)
Company Secretary & Executive Chairman
Comp: $626.24k
Ms. Vaidehi Joshi (Age 36)
Director of Discovery Biology & Director
Comp: $91.4k
Mr. Thomas P. Hess CPA (Age 59)
MBA, President & CFO
Dr. Curtis M. Tyree Ph.D.
Senior Vice President of Strategy & Business Development

Key Competitors

View All Competitors

Insiders

David Gobel
Sold 19,607 shares
Total: $31,763.34 ($1.62/share)

View All Insider Transactions

ONVO Stock Analysis - Frequently Asked Questions

How have ONVO shares performed in 2023?: Organovo's stock was trading at $1.41 at the beginning of the year. Since then, ONVO stock has decreased by 16.3% and is now trading at $1.18.
View the best growth stocks for 2023 here.
When is Organovo's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, February 8th 2024.
View our ONVO earnings forecast.
How were Organovo's earnings last quarter?: Organovo Holdings, Inc. (NASDAQ:ONVO) announced its earnings results on Thursday, August, 8th. The medical research company reported ($1.00) EPS for the quarter, hitting the consensus estimate of ($1.00). The medical research company earned $0.67 million during the quarter, compared to the consensus estimate of $0.77 million. Organovo had a negative trailing twelve-month return on equity of 129.61% and a negative net margin of 4,061.12%.
When did Organovo's stock split?: Organovo shares reverse split on Wednesday, August 19th 2020. The 1-20 reverse split was announced on Monday, August 17th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 18th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Taylor Crouch's approval rating as Organovo's CEO?: 3 employees have rated Organovo Chief Executive Officer Taylor Crouch on Glassdoor.com. Taylor Crouch has an approval rating of 38% among the company's employees. This puts Taylor Crouch in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Organovo own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Organovo investors own include Brainstorm Cell Therapeutics (BCLI), NVIDIA (NVDA), Aerojet Rocketdyne (AJRD), Blackstone (BX), LADENBURG THALM/SH SH (LTS), Advanced Micro Devices (AMD), Exelixis (EXEL), Micron Technology (MU), Novavax (NVAX) and OPKO Health (OPK).
Who are Organovo's major shareholders?: Organovo's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David Gobel and Douglas Jay Cohen.
View institutional ownership trends.
How do I buy shares of Organovo?: Shares of ONVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ONVO) was last updated on 11/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial